Jeff Baxter, VBI Vaccines CEO

First shot at pan-coro­n­avirus vac­cine dis­ap­points in VBI Vac­cines study

The first da­ta from a clin­i­cal tri­al of a vac­cine de­signed to pro­tect against many kinds of coro­n­avirus­es sug­gest that ef­forts to sig­nif­i­cant­ly im­prove over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.